The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid

References

• Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941;68:851-75
   Google Scholar
• Blot SI, Vandewoude KH, Hoste EA, et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-35
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). MRSA Among ICU Patients, 1995-2004. Available at: www.cdc.gov/ncidod/dhqp/pdf/ar/ICU_RESTrend1995-2004.pdf. [Last accessed 27 October 2008]
   Google Scholar
• Glezen WP. Prevention and treatment of seasonal influenza. N Engl J Med 2008;359:2579-85
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infection in children. Clin Infect Dis 2005;40:1785-91
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17
   PubMed Web of Science ®Google Scholar
• Dahm RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus [published correction in N Engl J Med 2007;357;1357]. N Engl J Med 2007;357:380-90
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. A 39-year-old man with a skin infection. JAMA 2008;299:79-87
   PubMed Web of Science ®Google Scholar
• Skrupky LP, Micek ST, Kollef MH. Optimizing therapy for MRSA pneumonia. Sem Respir Crit Care Med 2007;28:615-23
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97
   PubMed Web of Science ®Google Scholar
• Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6
   PubMed Web of Science ®Google Scholar
• Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-6
   PubMed Web of Science ®Google Scholar
• Itani KMF, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus. Am J Surg 2009 (in press)
   Google Scholar
• Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-62
   PubMed Web of Science ®Google Scholar
• Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006;42(Suppl 1):S51-7
   PubMedGoogle Scholar
• Goldstein F. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 2007;59:1-4
   PubMed Web of Science ®Google Scholar
• Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-8
   PubMed Web of Science ®Google Scholar
• Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45(Suppl 3):S191-5
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon JY. Ventilator associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903
   PubMed Web of Science ®Google Scholar
• Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S368-77
   PubMed Web of Science ®Google Scholar
• Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Outpatient management of skin and soft tissue infections in the era of community-associated MRSA. Available at www.cdc.gov/mrsa/mrsa_initiative/skin_infection/mrsa_algorithm.html [Last accessed 28 October 2008]
   Google Scholar
• Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(Suppl 1):S35-9
   PubMedGoogle Scholar
• Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;52:24-36
   PubMed Web of Science ®Google Scholar
• Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37:1132-6
   PubMed Web of Science ®Google Scholar
• Healy DP, Polk RE, Garson ML, et al. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987;31:393-7
   PubMed Web of Science ®Google Scholar
• Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002;49:155-60
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl S2):ii7-25
   Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003;47:2775-80
   PubMed Web of Science ®Google Scholar
• Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427-32
   PubMed Web of Science ®Google Scholar
• Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 2006;27:108-12
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22:91-7
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001;29(4 Suppl):N100-7
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006;26:539-50
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S378-85
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?. Clin Pharmacokinet 2008;47:147-52
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Lemaire F. Administration of antibiotics for pneumonia during respiratory failure: reaching the target. Am J Respir Crit Care Med 2001;164:1554-5
   PubMed Web of Science ®Google Scholar
• Rello J, Mallol J. Optimal therapy for methicillin-resistant Staphylococcus aureus pneumonia: what is the best dosing regimen?. Chest 2006;130:938-40
   PubMed Web of Science ®Google Scholar
• Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents. Am J Respir Med 2002;1:201-9
   PubMedGoogle Scholar
• Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?. Curr Opin Pharmacol 2007;7:498-504
   PubMed Web of Science ®Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn?. J Antimicrob Chemother 2008;61:235-7
   PubMed Web of Science ®Google Scholar
• Dykhuizen RS, Harvey G, Stephenson N, et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;39:1842-7
   PubMed Web of Science ®Google Scholar
• Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991;35:1947-52
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992;36:1171-5
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992;36:1176-80
   PubMed Web of Science ®Google Scholar
• Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006;50:2455-63
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-8
   PubMed Web of Science ®Google Scholar
• Byl B, Jacobs F, Wallemacq P, et al. Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 2003;47:2015-17
   PubMed Web of Science ®Google Scholar
• Conte JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80
   PubMed Web of Science ®Google Scholar
• Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431-4 [published erratum J Antimicrob Chemother 2003;52:536]
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetic and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529-33
   PubMed Web of Science ®Google Scholar
• Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004;48:1441-53
   PubMed Web of Science ®Google Scholar
• Daschner FD, Frank U, Kummer A, et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J Antimicrob Chemother 1987;19:359-62
   PubMed Web of Science ®Google Scholar
• Luzzati R, Sanna A, Allegranzi B, et al. Pharmacokinetics and tissue penetration of vancomycin in patients undergoing prosthetic mammary surgery. J Antimicrob Chemother 2000;45:243-5
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50:1372-5
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC, et al. Linezolid penetration into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-7
   PubMed Web of Science ®Google Scholar
• Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367-71
   PubMed Web of Science ®Google Scholar
• Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-23
   PubMed Web of Science ®Google Scholar
• Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64:1093-100. Published online 25 July 2008, doi:10.1007/s00228-008-0531-5
   PubMed Web of Science ®Google Scholar
• Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42(Suppl 1):S5-12
   PubMed Web of Science ®Google Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman J, McDougal LK, et al. Epidemiology and microbiological characteristics of infection caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States 1997-2001. Clin Infect Dis 2003;36:429-39
   PubMed Web of Science ®Google Scholar
• Miller D, Urdaneta V, Weltman A. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902
   PubMedGoogle Scholar
• Sievert DM, Boulton ML, Stolzman G, et al. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7
   PubMedGoogle Scholar
• Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health-Syst Pharm 2000;57(Suppl 2):S4-9 [correction in Am J Health-Syst Pharm 2001;58:78]
   PubMedGoogle Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-6
   PubMed Web of Science ®Google Scholar
• Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90
   PubMed Web of Science ®Google Scholar
• Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16:S31-4
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004;190:1140-9
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5
   PubMed Web of Science ®Google Scholar
• Lam AP, Wunderink RG. Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat. Semin Respir Crit Care Med 2006;27:92-103
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute, 2006
   Google Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin treatment for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006;166:2138-44
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-15
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Fritsche TR, et al. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006;57:279-87
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-17
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER program for 2007). Diagn Microbiol Infect Dis 2008;62:416-26
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003;17:479-501
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9
   PubMed Web of Science ®Google Scholar